Securities code: 688016 securities abbreviation: Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) Announcement No.: 2022-003 Shanghai minimally invasive Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) Technology (Group) Co., Ltd
Announcement on the appointment of senior managers
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Shanghai minimally invasive Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) Technology (Group) Co., Ltd. (hereinafter referred to as ” Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) ” or “the company”) has been reviewed by the nomination committee of the board of directors and approved at the fourth meeting of the second board of directors in accordance with the company law, the articles of Association and other relevant laws and regulations due to the needs of the company’s operation and development, Agree to appoint Mr. Liu Hao as the senior director of the company’s treatment scheme promotion and senior management of the company. The relevant information is hereby announced as follows:
1、 Deliberations of the board of directors
On February 9, 2022, the company held the fourth meeting of the second board of directors, deliberated and approved the proposal on the appointment of senior managers, and agreed to appoint Mr. Liu Hao as the senior director of the company’s treatment scheme promotion and senior managers of the company. The term of office starts from the date of deliberation and approval of this board of directors to the expiration of this board of directors.
As of the disclosure date of this announcement, Mr. Liu Hao did not directly hold shares of the company. Mr. Liu Hao has no relationship with directors, supervisors and senior managers of the company and shareholders holding more than 5% of the shares. Mr. Liu Hao has not been punished by the CSRC and other relevant departments or the stock exchange; Their qualifications and nomination procedures comply with the provisions of the company law, the articles of association and other relevant laws. Mr. Liu Hao’s resume is detailed in the annex to this announcement.
2、 Independent opinions of independent directors
After examination, it is not found that Mr. Liu Hao is not allowed to serve as the senior management of the company as stipulated in the company law and the articles of association, and Mr. Liu Hao has not been punished by the CSRC and other relevant departments or the Shanghai Stock Exchange; The qualifications of senior managers of the company in accordance with relevant laws, regulations, normative documents and the articles of Association; The procedures for the appointment of senior managers comply with the company law, securities law and other laws, administrative regulations and the relevant provisions of the articles of association.
We agree to appoint Mr. Liu Hao as the senior management of the company, and the term of office is consistent with that of the second board of directors of the company.
It is hereby announced.
Board of directors of Shanghai minimally invasive Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) Technology (Group) Co., Ltd. February 11, 2022 attached: resume of Liu Hao
Liu Hao, male, born in November 1984, Chinese nationality, without permanent residency abroad, bachelor degree. From October 2009 to may 2011, he served as the sales representative of Beijing haienkang Technology Co., Ltd. From July 2011 to April 2013, he served as the sales supervisor of Shanghai Shengmai medical device Co., Ltd. Since May 2013, he has successively served as Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) sales representative, sales director, sales manager, sales director and senior sales director.
Up to now, Mr. Liu Hao has not directly held the company’s shares, has no relationship with the controlling shareholder and actual controller of the company, shareholders holding more than 5% of the company’s shares, directors, supervisors and senior managers of the company, and has not been punished by China Securities Regulatory Commission and other relevant departments or Shanghai Stock Exchange, Not suspected of committing a crime, being filed for investigation by the judicial organ or suspected of violating laws and regulations, being filed for inspection by the CSRC, not being a dishonest person, and meeting the qualifications required by relevant laws, administrative regulations, departmental rules, normative documents, etc.
